US009511038B2

(12) **United States Patent**
Dohil et al.

(10) **Patent No.: US 9,511,038 B2**
(45) **Date of Patent: *Dec. 6, 2016**

(54) **METHODS OF TREATING NON-ALCOHOLIC STEATOHEPATITIS (NASH) USING CYSTEAMINE PRODUCTS**

(71) Applicant: **The Regents of the University of California**, Oakland, CA (US)

(72) Inventors: **Ranjan Dohil**, San Diego, CA (US); **Jerry Schneider**, La Jolla, CA (US)

(73) Assignee: **The Regents of the University of California**, Oakland, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/867,386**

(22) Filed: **Sep. 28, 2015**

(65) **Prior Publication Data**

US 2016/0143865 A1 May 26, 2016

Related U.S. Application Data

(63) Continuation of application No. 13/608,134, filed on Sep. 10, 2012, now Pat. No. 9,149,448, which is a continuation of application No. 13/183,990, filed on Jul. 15, 2011, now Pat. No. 8,263,662, which is a continuation of application No. 12/745,504, filed as application No. PCT/US2008/085064 on Nov. 28, 2008, now Pat. No. 7,994,226.

(60) Provisional application No. 60/991,517, filed on Nov. 30, 2007, provisional application No. 61/085,397, filed on Jul. 31, 2008.

(51) **Int. Cl.**

A01N 33/08	(2006.01)
A61K 31/145	(2006.01)
A61K 9/48	(2006.01)
A61K 45/06	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 31/145*** (2013.01); ***A61K 9/4891*** (2013.01); ***A61K 45/06*** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,324,743	A	4/1982	Feuer	
4,959,306	A	9/1990	Kameda	
5,668,117	A	9/1997	Shapiro	
6,331,316	B1	12/2001	Ullah et al.	
6,794,414	B1	9/2004	Steinman	
7,449,451	B2	11/2008	Prasad et al.	
7,994,226	B2 *	8/2011	Dohil	A61K 9/4891 424/474
8,026,284	B2	9/2011	Dohil et al.	
8,129,433	B2	3/2012	Dohil et al.	
8,263,662	B2 *	9/2012	Dohil	A61K 9/4891 424/474
9,149,448	B2 *	10/2015	Dohil	A61K 9/4891
2003/0157191	A1	8/2003	Kil	
2003/0162747	A1	8/2003	Kil	
2004/0033985	A1	2/2004	Chi	
2004/0106591	A1	6/2004	Pacioretty	
2005/0027015	A1	2/2005	Chi et al.	
2005/0137125	A1	6/2005	Chan et al.	
2005/0209441	A1	9/2005	Lile	
2005/0245433	A1	11/2005	Chan	
2006/0140906	A1	6/2006	Chi et al.	
2007/0078113	A1	4/2007	Roth	
2007/0172514	A1	7/2007	Chi	
2009/0023632	A1	1/2009	Adamson et al.	
2009/0076166	A1	3/2009	Dohil et al.	

FOREIGN PATENT DOCUMENTS

JP	2004-026716	A	1/2004
TW	1478710	B	4/2015
WO	03/070020	A1	8/2003
WO	2005/049002	A1	6/2005
WO	2005/063226	A1	7/2005
WO	2005/107730	A2	11/2005
WO	2006/072259	A2	7/2006
WO	2007/121545	A1	11/2007
WO	2007130636	A2	11/2007
WO	2008/093764	A1	8/2008
WO	2009/070781	A1	4/2009

OTHER PUBLICATIONS

Raptor Pharmaceutical Corp., "DR Cysteamine: Non-Alcoholic Steatohepatitis (NASH)," Rodman & Renshaw 10th Annual Healthcare Conference, Nov. 11, 2008.

Raptor Pharmaceutical Corp., "DR Cysteamine: Non-Alcoholic Steatohepatitis (NASH)," Investor Presenation, Summer 2008.

Raptor Pharmaceutical Corp., "NEW DR Cysteamine Markets," 26th Annual JP MOrgan Annual Healthcare Conference, Jan. 7-10, 2008.

Raptor Pharmaceutical Corp., "Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline," http://ir.raptorpharma.com/phoenix.zhtml?c=198466&p=irol-newsArticle&ID=1120014&highlight=nash, Mar. 19, 2008.

Raptor Pharmaceutical Corp., "Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease," http://ir.raptorpharma.com/phoenix.zhtml?c=198466&p=irol-newsArticle&ID=1163467&highlight=nash, Jun. 9, 2008.

Raptor Pharmaceutical Corp., "Raptor Pharmaceuticals Corp. to Present at BIO 2008 International Convention," http://ir.raptorpharma.com/phoenix.zhtml?c=198466&p=irol-newsArticle&ID=1165084&highlight=nash, Jun. 12, 2008.

(Continued)

Primary Examiner — Hasan Ahmed

(74) *Attorney, Agent, or Firm* — Joseph R. Baker, Jr.; Gavrilovich, Dodd & Lindsey LLP

(57) **ABSTRACT**

The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine products. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

27 Claims, 7 Drawing Sheets